uniQure shares surge 11.37% after-hours as H.C. Wainwright reaffirms $70 Buy rating amid regulatory discussions.

uniQure (NASDAQ:QURE) surged 11.37% in after-hours trading following H.C. Wainwright’s reaffirmation of a Buy rating and $70 price target, maintaining a positive outlook despite ongoing regulatory discussions. The firm highlighted the upcoming FDA Type A meeting as a critical near-term catalyst, potentially resolving regulatory uncertainty for AMT-130, its Huntington’s disease gene therapy. While prior FDA concerns and analyst downgrades had pressured the stock, Wainwright’s endorsement—emphasizing confidence in AMT-130’s data and regulatory pathways—appears to have driven the sharp post-market rebound. The move aligns with broader analyst optimism, though challenges remain regarding AMT-130’s approval timeline.